Assessing abuse potential of new analgesic medications following market release: An evaluation of internet discussion of tapentadol abuse

Pain Medicine (United States)

Volumn 16, Issue 1, 2015, Pages 131-140

  Mcnaughton, Emily C ^a   Black, Ryan A ^b   Weber, Sarah E ^a   Butler, Stephen F ^a  

^a INFLEXXION INC   (United States)

^b NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

Abuse liability; Abuse risk; Endorsement ratio; Internet monitoring; NAVIPPRO; Opioid; Tapentadol

Indexed keywords

BUPRENORPHINE; FENTANYL; HYDROCODONE; HYDROMORPHONE; MORPHINE; OXYCODONE; OXYMORPHONE; RECREATIONAL DRUG; TAPENTADOL; TRAMADOL; NARCOTIC ANALGESIC AGENT; PHENOL DERIVATIVE;

ARTICLE; DRUG ABUSE; DRUG MARKETING; DRUG MONITORING; HUMAN; INTERNET; ONLINE SYSTEM; PAIN; PRESCRIPTION; OPIOID-RELATED DISORDERS; SOCIAL MEDIA;

ANALGESICS, OPIOID; HUMANS; OPIOID-RELATED DISORDERS; PHENOLS; SOCIAL MEDIA;

EID: 84921498422     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/pme.12547     Document Type: Article

References (45)

1. Compton WM, Volkow ND. Major increases in opioid analgesic abuse in the United States: Concerns and strategies. Drug Alcohol Depend 2006;81(2):103-107.
2. Substance Abuse and Mental Health Services Administration. Results from the 2009 National Survey on Drug Use and Health: Volume I. Summary of national findings. Rockville, MD: Office of Applied Studies, NSDUH, HHS Publication No. SMA 10-4856 Findings; 2010. Available at: http://www.samhsa.gov/data/NSDUH/2k9NSDUH/2k9Results.html (accessed August 2014).
3. FDA. Risk Evaluation and Mitigation Strategies (REMS) for extended-release and long-acting opioid analgesics. 2010. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndLifeSupport DrugsAdvisoryCommittee/UCM217510.pdf (accessed August 2014).
4. Manchikanti L, Fellows B, Ailinani H, Pampati V. Therapeutic use, abuse, and nonmedical use of opioids: A ten-year perspective. Pain Physician 2010;13(2):401-435.
5. ONDCP. Epidemic: Responding to America's Prescription Drug Abuse Crisis. 2011.
6. Butler SF, McNaughton EC, Black RA. Tapentadol abuse potential: A post-marketing evaluation using a sample of individuals evaluated for substance abuse treatment. Pain Med 2014. DOI: 10.1111/pme.12524
7. Janssen Pharmaceuticals, Inc. Nucynta® ER [Package Insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2011. Revised 2014.
8. Tzschentke TM, Jahnel U, Koegel B, Christoph T, Englberger W. Tapentadol hydrochloride: A next-generation, centrally acting analgesic with two mechanisms of action in a single molecule. Drugs Today 2009;45(7):483-496.
9. Vadivelu N, Timchenko A, Huang Y, Sinatra R. Tapentadol extended-release for treatment of chronic pain: A review. J Pain Res 2011;4:211-218.
10. Tzschentke TM, Christoph T, Ko B, etal. (-)-(1R, 2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): A novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther 2007;323(1):265-276.
11. Vorsanger G, Xiang J, Okamoto A, Upmalis D, Moskovitz B. Evaluation of study discontinuations with tapentadol immediate release and oxycodone immediate release in patients with low back or osteoarthritis pain. J Opioid Manag 2010;6(3):169-179.
12. Afilalo M, Etropolski MS, Kuperwasser B, etal. Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: A randomized, double-blind, placebo- and active-controlled phase III. Clin Drug Investig 2010;30(8):489-505.
13. Buynak R, Shapiro D, Okamoto A, etal. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: Results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study. Expert Opin Pharmacother 2010;11(11):1787-1804.
14. Daniels SE, Upmalis D, Okamoto A, Lange C, Häeussler J. A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain. Curr Med Res Opin 2009;25(3):765-776.
15. Daniels SE, Casson E, Stegmann JU, etal. A randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain. Curr Med Res Opin 2009;25(6):1551-1561.
16. Hartrick C, Van Hove I, Stegmann JU, Oh C, Upmalis D. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: A 10-day, phase III, randomized, double-blind, active- and placebo-controlled. Clin Ther 2009;31(2):260-271.
17. Terlinden R, Ossig J, Fliegert F, Lange C, Göhler K. Absorption, metabolism and excretion of 14C-labeled tapentadol HCl in healthy male subjects. Eur J Drug Metab Pharmacokinet 2007;32(3):163-169.
18. Wee S, Woolverton WL. Evaluation of the reinforcing effects of atomoxetine in monkeys: Comparison to methylphenidate and desipramine. Drug Alcohol Depend 2004;75(3):271-276.
19. Le Merrer J, Becker JAJ, Befort K, Kieffer BL. Reward processing by the opioid system in the brain. Physiol Rev 2009;89(4):1379-1412.
20. Zhang Z, Pan ZZ. Synaptic mechanism for functional synergism between delta- and mu-opioid receptors. J Neurosci 2010;30(13):4735-4745.
21. DEA. Schedules of controlled substances: Placement of tapentadol into schedule II. Final rule. Fed Regist 2009;74(97):23790-23793.
22. Dart RC, Cicero TJ, Surratt HL, etal. Assessment of the abuse of tapentadol immediate release: The first 24 months. J Opioid Manag 2012;8(6):395-402.
23. Cepeda MS, Fife D, Vo L, Mastrogiovanni G, Yuan Y. Comparison of opioid doctor shopping for tapentadol and oxycodone: A cohort study. J Pain 2013;14(2):158-164.
24. Arfken CL, Cicero TJ. Postmarketing surveillance for drug abuse. Drug Alcohol Depend 2003;70(3):S97-S105.
25. Schifano F, Deluca P, Baldacchino A, etal. Drugs on the web; The Psychonaut 2002 EU project. Prog Neuropsychopharmacol Biol Psychiatry 2006;30(4):640-646.
26. Mounteney J, Leirvåg S-E. Providing an earlier warning of emerging drug trends: The føre var system. Drugs Educ Prev Policy 2004;11(6):449-471.
27. Gordon SM, Forman RF, Siatkowski C. Knowledge and use of the internet as a source of controlled substances. J Subst Abuse Treat 2006;30(3):271-274.
28. Boyer EW, Lapen PT, Macalino G, Hibberd PL. Dissemination of psychoactive substance information by innovative drug users. Cyberpsychol Behav 2007;10(1):1-6.
29. Wax PM. Just a click away: Recreational drug web sites on the Internet. Pediatrics 2002;109(6):e96. Available at: http://pediatrics.aappublications.org/cgi/doi/10.1542/peds.109.6.e96 (accessed November 2012). [Internet].
30. Zinkhan GM, Kwak H, Morrison M, Peters CO. Web-based chatting: Consumer communication in cyberspace. J Consum Psychol 2003;13(1-2):17-27.
31. Nielsen S, Barratt MJ. Prescription drug misuse: Is technology friend or foe? Drug Alcohol Rev 2009;28(1):81-86.
32. Abratt R, Nel D, Nezer C. Role of the market maven in retailing: A general marketplace influencer. J Bus Psychol 1995;10:31-56.
33. Walsh G, Gwinner KP, Swanson SR. What makes mavens tick? Exploring the motives of market mavens' initiation of information diffusion. J Consum Mark 2004;21(2):109-122.
34. Bei L, Chen EYI, Widdows R. Consumers' online information search behavior and the phenomenon of search vs. experience products. J Fam Econ Issues 2004;25(4):449-467.
35. Nonnecke B, Preece J. Lurker Demographics: Counting the Silent. Proc CHI 2000. 2000;1-8.
36. Rogers E. Diffusion of Innovations. New York: Free Press; 1995.
37. Gladwell M. The Tipping Point. New York: Abacus; 2000.
38. Butler SF, Venuti SW, Benoit C, etal. Internet surveillance: Content analysis and monitoring of product-specific internet prescription opioid abuse-related postings. Clin J Pain 2007;23(7):619-628.
39. McNaughton EC, Black RA, Zulueta MG, Budman SH, Butler SF. Measuring online endorsement of prescription opioids abuse: An integrative methodology. Pharmacoepidemiol Drug Saf 2012;21(10):1081-1092.
40. Butler SF, Black RA, Cassidy TA, Dailey TM, Budman SH. Abuse risks and routes of administration of different prescription opioid compounds and formulations. Harm Reduct J 2011;8(29):1-17. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3213066&tool=pmcentrez&rendertype=abstract (accessed November 2012). [Internet]. BioMed Central Ltd.
41. Dasgupta N, Kramer ED, Zalman M-A, etal. Association between non-medical and prescriptive usage of opioids. Drug Alcohol Depend 2006;82(2):135-142.
42. Landis J, Koch G. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-174.
43. Neuendorf KA. Content Analysis Guidebook. Thousand Oaks, CA: Sage Publications; 2002.
44. Adams EH, Breiner S, Cicero TJ, etal. A comparison of the abuse liability of tramadol, NSAIDs, and hydrocodone in patients with chronic pain. J Pain Symptom Manage 2006;31(5):465-476.
45. Cicero TJ, Adams EH, Geller A, etal. A postmarketing surveillance program to monitor Ultram (tramadol hydrochloride) abuse in the United States. Drug Alcohol Depend 1999;57(1):7-22.